Sirtuins--novel therapeutic targets to treat age-associated diseases.
Sirtuins post-translationally modulate the function of many cellular proteins that undergo reversible acetylation-deacetylation cycles, affecting physiological responses that have implications for treating diseases of ageing. Potent small-molecule modulators of sirtuins have shown efficacy in preclinical models of metabolic, neurodegenerative and inflammatory diseases, and so hold promise for drug discovery efforts in multiple therapeutic areas. Here, we discuss current knowledge and data that strengthens sirtuins as a druggable set of enzymes for the treatment of age-associated diseases, including activation of SIRT1 in type 2 diabetes.
Lavu
Siva
S
Sirtris Pharmaceuticals, Cambridge, Massachusetts 02139, USA.
Boss
Olivier
O
Elliott
Peter J
PJ
Lambert
Philip D
PD
D000375:Aging / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D031204:Caloric Restriction / Q000379:methods; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000201:enzymology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000201:enzymology; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D037761:Sirtuins / Q000819:agonists / Q000378:metabolism*
D037761:Sirtuins